{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:22:45Z","timestamp":1791256965787,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.exphem.2012.10.005","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T02:01:01Z","timestamp":1350439261000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia"],"prefix":"10.1016","volume":"41","author":[{"given":"Teresa","family":"Bernal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Moncada-Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Soria-Valles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Guti\u00e9rrez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.10.005_bib1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib2","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","article-title":"Myelodysplastic syndromes","volume":"111","author":"Nimer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase iii study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2012.10.005_bib4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib5","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V91.8.2985.2985_2985_2990","article-title":"Methylation of the p15(ink4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression","volume":"91","author":"Quesnel","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib6","doi-asserted-by":"crossref","first-page":"16811","DOI":"10.1073\/pnas.0907109106","article-title":"Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS","volume":"106","author":"Follo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2012.10.005_bib7","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","article-title":"Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies","volume":"114","author":"Fandy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"Nf-kappab constitutes a potential therapeutic target in high-risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.4161\/cc.7.14.6268","article-title":"A novel effect of DNA methyltransferase and histone deacetylase inhibitors: Nfkappab inhibition in malignant myeloblasts","volume":"7","author":"Fabre","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.exphem.2012.10.005_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/epi.5.3.11409","article-title":"5-azacytidine treatment reorganizes genomic histone modification patterns","volume":"5","author":"Komashko","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.exphem.2012.10.005_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/gcc.20877","article-title":"Dnmt3b gene amplification predicts resistance to DNA demethylating drugs","volume":"50","author":"Simo-Riudalbas","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2012.10.005_bib12","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2012.10.005_bib13","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.005_bib14","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2009.26.3509","article-title":"Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome","volume":"28","author":"Faderl","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.exphem.2012.10.005_bib15","doi-asserted-by":"crossref","first-page":"e23372","DOI":"10.1371\/journal.pone.0023372","article-title":"Mechanisms of resistance to decitabine in the myelodysplastic syndrome","volume":"6","author":"Qin","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.exphem.2012.10.005_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jnci\/95.4.327","article-title":"Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness","volume":"95","author":"Sato","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2012.10.005_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2012.10.005_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbamcr.2009.07.004","article-title":"Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models","volume":"1803","author":"Fanjul-Fernandez","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2012.10.005_bib19","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1242\/jcs.050468","article-title":"The adamts12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer","volume":"122","author":"Moncada-Pazos","year":"2009","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.exphem.2012.10.005_bib20","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1158\/0008-5472.CAN-08-4155","article-title":"Genetic inactivation of adamts15 metalloprotease in human colorectal cancer","volume":"69","author":"Viloria","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2012.10.005_bib21","first-page":"1115","article-title":"Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes","volume":"5","author":"Ries","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2012.10.005_bib22","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1096\/fj.10-174904","article-title":"Oxldl up-regulates microrna-29b, leading to epigenetic modifications of mmp-2\/mmp-9 genes: a novel mechanism for cardiovascular diseases","volume":"25","author":"Chen","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2012.10.005_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib24","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0092-8674(02)00754-7","article-title":"Recruitment of stem and progenitor cells from the bone marrow niche requires mmp-9 mediated release of kit-ligand","volume":"109","author":"Heissig","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2012.10.005_bib27","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.2174\/092986710794183033","article-title":"The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia","volume":"17","author":"Hatfield","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.exphem.2012.10.005_bib28","first-page":"402","article-title":"Expression of matrix metalloproteinases (mmp-2 and -9) and tissue inhibitors of metalloproteinases (timp-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells","volume":"105","author":"Janowska-Wieczorek","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4161\/cc.7.8.5645","article-title":"Cell-surface mmp-9 regulates the invasive capacity of leukemia blast cells with monocytic features","volume":"7","author":"Paupert","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.exphem.2012.10.005_bib30","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2008-04-148643","article-title":"Role of leukemia cell invadosome in extramedullary infiltration","volume":"114","author":"Stefanidakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.10.005_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1365-2141.2002.03510.x","article-title":"Marrow matrix metalloproteinases (mmps) and tissue inhibitors of mmp in acute leukaemia: potential role of mmp-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia","volume":"117","author":"Lin","year":"2002","journal-title":"Br J\u00a0Haematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.2007.01012.x","article-title":"Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes","volume":"80","author":"Travaglino","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2144\/05381RV01","article-title":"Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors","volume":"38","author":"Snoek-van Beurden","year":"2005","journal-title":"Biotechniques"},{"key":"10.1016\/j.exphem.2012.10.005_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jcp.20948","article-title":"Regulation of matrix metalloproteinase gene expression","volume":"211","author":"Yan","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2012.10.005_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0006-291X(02)02283-0","article-title":"Evidence for the role of promoter methylation in the regulation of mmp-9 gene expression","volume":"297","author":"Chicoine","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2012.10.005_bib36","first-page":"573","article-title":"The anti-leukemic effect of a novel histone deacetylase inhibitor mct-1 and 5-aza-cytidine involves augmentation of nur77 and inhibition of mmp-9 expression","volume":"34","author":"Liu","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.exphem.2012.10.005_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.exphem.2005.09.007","article-title":"A pharmacodynamic study of 5-azacytidine in the p39 cell line","volume":"34","author":"Khan","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.exphem.2007.10.002","article-title":"Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells","volume":"36","author":"Khan","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2012.10.005_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-60761-863-8_12","article-title":"Epigenetic regulation of microrna expression in cancer","volume":"676","author":"Choudhry","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2012.10.005_bib40","doi-asserted-by":"crossref","first-page":"e19027","DOI":"10.1371\/journal.pone.0019027","article-title":"Epigenetic inactivation of the mir-124-1 in haematological malignancies","volume":"6","author":"Wong","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.exphem.2012.10.005_bib41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrc884","article-title":"Strategies for mmp inhibition in cancer: innovations for the post-trial era","volume":"2","author":"Overall","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2012.10.005_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc2823","article-title":"The regulatory crosstalk between kinases and proteases in cancer","volume":"10","author":"Lopez-Otin","year":"2010","journal-title":"Nat Rev Cancer"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12004365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12004365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:53Z","timestamp":1759566653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12004365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0301472X12004365"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.10.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}